Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial

BACKGROUND: The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients. METHODS/DESIGN: Inclusion criteria are adult patients with stage 4 or 5 chronic kidney disease (including d...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, David Wayne, Hawley, Carmel Mary, Rosser, Brenda, Beller, Elaine, Thompson, Charles, Fassett, Robert G, Ferrari, Paolo, MacDonald, Stephen, Pedagogos, Eugenie, Cass, Alan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519060/
https://www.ncbi.nlm.nih.gov/pubmed/18671885
http://dx.doi.org/10.1186/1471-2369-9-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519060/
https://www.ncbi.nlm.nih.gov/pubmed/18671885
http://dx.doi.org/10.1186/1471-2369-9-8

Ejemplares similares